Oral presentation by Dr. Meletios A Dimopoulos
Currently, in Canada, treatment options for patients beyond three lines of therapy are limited outside of clinical trials. In this phase II trial, the median number of prior lines was 4, making the results relevant in terms of a significant unmet need for Canadian patients.
In this study, patients with multiple myeloma (MM) who had previously received an immunomodulatory drug and a proteasome inhibitor were enrolled. They received either isatuximab or isatuximab in combination with dexamethasone. The authors evaluated the overall response rate (ORR) of isatuximab both as monotherapy and in combination with dexamethasone in this patient population.
Isatuximab monotherapy had a duration of response (DOR) of 18.9 weeks and an ORR of 26%. Isatuximab in combination with dexamethasone had a DOR of 30 weeks and an ORR of 44% with 18% of patients achieving a very good partial response or better.
The availability of a monoclonal antibody in Canada is currently limited for patients with relapsed/refractory MM. However, there have been a significant number of studies that have demonstrated a benefit of this new class of agents for these patients. Given that this study demonstrated efficacy in this very difficult and heavily pre-treated population, it is likely that studies incorporating this drug in earlier lines and in various combinations will allow patients to benefit even further.